These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 26472021

  • 41. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
    Yin MZ, Ma J, He Q, Shen P, Chen JF, Jin XT, Zhang ZD, Kuick CH, Chen HY, Ng EHQ, Aw SJ, Chang KTE.
    Zhonghua Bing Li Xue Za Zhi; 2020 Jul 08; 49(7):675-680. PubMed ID: 32610377
    [Abstract] [Full Text] [Related]

  • 42. Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation.
    Bounacer A, Schlumberger M, Wicker R, Du-Villard JA, Caillou B, Sarasin A, Suárez HG.
    Br J Cancer; 2000 Jan 08; 82(2):308-14. PubMed ID: 10646882
    [Abstract] [Full Text] [Related]

  • 43. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
    Cook PJ, Thomas R, Kannan R, de Leon ES, Drilon A, Rosenblum MK, Scaltriti M, Benezra R, Ventura A.
    Nat Commun; 2017 Jul 11; 8():15987. PubMed ID: 28695888
    [Abstract] [Full Text] [Related]

  • 44. N of 2 Responders with LMNA-NTRK1.
    Lih CJ, Chen AP.
    J Natl Cancer Inst; 2016 Jan 11; 108(1):. PubMed ID: 26563357
    [No Abstract] [Full Text] [Related]

  • 45. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
    Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.
    Mol Cancer Ther; 2016 Apr 11; 15(4):628-39. PubMed ID: 26939704
    [Abstract] [Full Text] [Related]

  • 46. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
    Vingiani A, Lorenzini D, Conca E, Volpi CC, Trupia DV, Gloghini A, Perrone F, Tamborini E, Dagrada GP, Agnelli L, Capone I, Busico A, Pruneri G.
    Cancer Biomark; 2023 Apr 11; 38(3):301-309. PubMed ID: 37545217
    [Abstract] [Full Text] [Related]

  • 47. Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study.
    Hyrcza MD, Martins-Filho SN, Spatz A, Wang HJ, Purgina BM, Desmeules P, Park PC, Bigras G, Jung S, Cutz JC, Xu Z, Berman DM, Sheffield BS, Cheung CC, Leduc C, Hwang DM, Ionescu D, Klonowski P, Chevarie-Davis M, Chami R, Lo B, Stockley TL, Tsao MS, Torlakovic E.
    Mod Pathol; 2024 Jan 11; 37(1):100384. PubMed ID: 37972928
    [Abstract] [Full Text] [Related]

  • 48. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
    Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA, Peled N.
    Oncologist; 2015 Mar 11; 20(3):316-22. PubMed ID: 25721120
    [Abstract] [Full Text] [Related]

  • 49. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C.
    J Natl Cancer Inst; 2017 Dec 01; 109(12):. PubMed ID: 29370427
    [Abstract] [Full Text] [Related]

  • 50. The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B-NTRK1 fusion.
    Shinozaki-Ushiku A, Ishikawa S, Komura D, Seto Y, Aburatani H, Ushiku T.
    Gastric Cancer; 2020 Sep 01; 23(5):944-947. PubMed ID: 32189226
    [Abstract] [Full Text] [Related]

  • 51. Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma.
    Brzeziańska E, Pastuszak-Lewandoska D, Lewiński A.
    Neuro Endocrinol Lett; 2007 Jun 01; 28(3):221-9. PubMed ID: 17627253
    [Abstract] [Full Text] [Related]

  • 52. Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1.
    Musholt TJ, Brehm C, Hanack J, von Wasielewski R, Musholt PB.
    J Surg Res; 2006 Mar 01; 131(1):15-25. PubMed ID: 16256137
    [Abstract] [Full Text] [Related]

  • 53. Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors.
    Agaram NP, Zhang L, Sung YS, Chen CL, Chung CT, Antonescu CR, Fletcher CD.
    Am J Surg Pathol; 2016 Oct 01; 40(10):1407-16. PubMed ID: 27259011
    [Abstract] [Full Text] [Related]

  • 54. A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes.
    Suurmeijer AJH, Dickson BC, Swanson D, Zhang L, Sung YS, Cotzia P, Fletcher CDM, Antonescu CR.
    Genes Chromosomes Cancer; 2018 Dec 01; 57(12):611-621. PubMed ID: 30276917
    [Abstract] [Full Text] [Related]

  • 55. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
    Pandre MK, Shaik S, Satya Pratap VVV, Yadlapalli P, Yanamandra M, Mitra S.
    Anal Biochem; 2018 Mar 15; 545():78-83. PubMed ID: 29360440
    [Abstract] [Full Text] [Related]

  • 56. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L.
    Expert Opin Investig Drugs; 2015 Mar 15; 24(11):1493-500. PubMed ID: 26457764
    [Abstract] [Full Text] [Related]

  • 57. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma.
    Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF, Klempnauer J.
    Surgery; 2000 Dec 15; 128(6):984-93. PubMed ID: 11114633
    [Abstract] [Full Text] [Related]

  • 58. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
    Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke S, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MR, O'Toole SA, Cooper WA.
    Histopathology; 2017 Feb 15; 70(3):402-411. PubMed ID: 27599111
    [Abstract] [Full Text] [Related]

  • 59. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.
    Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z, Multani P, Murphy D, Shoemaker R, Lauricella C, Giannetta L, Maiolani M, Vanzulli A, Ardini E, Galvani A, Isacchi A, Sartore-Bianchi A, Siena S.
    Br J Cancer; 2015 Dec 22; 113(12):1730-4. PubMed ID: 26633560
    [Abstract] [Full Text] [Related]

  • 60. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma.
    Macerola E, Proietti A, Poma AM, Vignali P, Sparavelli R, Ginori A, Basolo A, Elisei R, Santini F, Basolo F.
    Int J Mol Sci; 2022 Jul 05; 23(13):. PubMed ID: 35806472
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.